PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66570-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)66570-9/fulltext
Title :
PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66570-9&doi=10.1016/S1098-3015(10)66570-9
First page :
Section Title :
Open access? :
No
Section Order :
405